Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.

Russell Moser¹, Kay E Gurley¹, Olga Nikolova², Guangrong Qin³, Rashmi Joshi⁴, Eduardo Mendez, Ilya Shmulevich³, Amanda Ashley⁴, Carla Grandori⁵, Christopher J Kemp⁶

¹Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

²Division of Oncological Sciences, Oregon Health and Science University, Portland, OR, USA.

³Institute for Systems Biology, Seattle, WA, USA.

⁴New Mexico State University, Las Cruces, NM, USA.

⁵SEngine Precision Medicine, Seattle, WA, USA.

⁶Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. cjkemp@fhcrc.org.

PubMed DOI

Abstract

The oncogene Ras and the tumor suppressor gene p53 are frequently co-mutated in human cancer and mutations in Ras and p53 can cooperate to generate a more malignant cell state. To discover novel druggable targets for cancers carrying co-mutations in Ras and p53, we performed arrayed, kinome focused siRNA and oncology drug phenotypic screening utilizing a set of syngeneic Ras mutant squamous cell c…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.